Despite its therapeutic potential, current understanding of Nrf2 largely stems from in vitro and acute rodent studies, with minimal validation in genetically diverse ALS models or patient-derived organoids. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.